{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000904","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2022-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.220448+00:00","generated_at":"2026-06-24T08:58:56.949723+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Teva Q2 revenue $3.8B, non-GAAP EPS $0.68; reaches $4.25B opioids settlement in principle","bullets":["Revenue $3.8B (-3% YoY, +1% local currency); GAAP loss $0.21, non-GAAP EPS $0.68 vs $0.59 prior year","Agreed in principle to nationwide opioids settlement: up to $4.25B + $100M for tribes over 13 years, includes Narcan supply","Revised 2022 revenue guidance to $15.0-$15.6B from $15.4-$16.0B due to FX; reaffirmed adjusted EBITDA, EPS, FCF","COPAXONE outlook lowered to ~$700M from ~$750M; non-GAAP tax rate outlook cut to 13%-14% from 18%-19%","Cash flow from ops $123M, free cash flow $301M; goodwill impairment and legal settlements drove GAAP loss"],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000904","json":"https://secwatch.observer/filing/0001157523-22-000904.json","markdown":"https://secwatch.observer/filing/0001157523-22-000904.md","text":"https://secwatch.observer/filing/0001157523-22-000904.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000115752322000904/0001157523-22-000904-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000115752322000904/a52792738.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:58:56.949723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}